問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Thoracic Medicine

Division of Cardiovascular Diseases

Division of Hematology & Oncology

Division of General Internal Medicine

National Taiwan University Cancer Center (在職)

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of General Internal Medicine

更新時間：2023-09-19

林彥廷LIN, YEN-TING
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

  • test@ntuh.gov.tw

Recruiting Trial

200Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林彥廷

List

247Cases

2022-08-01 - 2027-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2024-04-30 - 2027-04-30

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2019-09-01 - 2019-08-06

Phase III

Regarding tislelizumab (BGB-A317) combined with chemotherapy and radiotherapy followed by tislelizumab monotherapy for use in newly diagnosed, locally advanced, unresectable stage III non-small cell lung cancer subjects for a phase 3, random assignment, double blind, Placebo controlled trial.

  • Condition/Disease

    NSCLC

  • Test Drug

    Tislelizumab

Participate Sites
8Sites

Recruiting3Sites

Terminated5Sites

2020-05-01 - 2025-05-31

Phase III

A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

  • Condition/Disease

    A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

  • Test Drug

    TAK-788 (AP32788)

Participate Sites
9Sites

Recruiting9Sites

2023-12-01 - 2028-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2023-12-01 - 2024-09-16

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2022-10-01 - 2024-12-12

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-04-01 - 2028-12-31

Phase I/II

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

  • Condition/Disease

    c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

  • Test Drug

    APL-101

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2021-11-16 - 2024-02-06

Phase I/II

A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    NM21-1480

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2023-12-01 - 2031-05-31

Phase III

A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater than or Equal to 50%

  • Condition/Disease

    Non-small Cell Lung Cancer (NSCLC)

  • Test Drug

    MK-2870Keytruda Injection

Participate Sites
8Sites

Recruiting8Sites

1 20 21 22 23 24 25
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB